Actively Recruiting

Phase 3
Age: 18Years - 70Years
All Genders
ID07496034

Efficacy of Gou-Teng-San (GTS) in Patients With Episodic Migraine: A Double-Blind Randomized Controlled Trial (GTSEM Trial)

Led by Tsai, Chueh-Yi, MD · Updated on 2026-05-20

40

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

Sponsors

T

Tsai, Chueh-Yi, MD

Lead Sponsor

C

Chung Shan Medical University

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating whether Gou-Teng-San (GTS), a traditional herbal medicine, is effective and safe for adults with episodic migraine. This Phase 3 double-blind randomized controlled trial aims to see if GTS can reduce the number of migraine days, improve migraine symptoms, and lessen the impact of migraines on daily life. Safety and tolerability will be monitored throughout the study period. Participants will be randomly assigned to receive either Gou-Teng-San or a placebo (starch), both given orally at a dose of 5 grams twice daily, once in the morning and once in the evening, for 4 consecutive weeks. The study includes a screening period followed by the 4-week treatment phase. During the study, participants will track their migraines using a headache diary and undergo assessments to measure changes in migraine frequency from baseline to the fourth week. Researchers will also monitor safety, tolerability, and participant compliance. The primary outcome is the change in the average number of migraine days per month after 4 weeks of treatment.

CONDITIONS

Brief Title

Efficacy of Gou-Teng-San (GTS) in Patients With Episodic Migraine

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 to 70 years
  • History of episodic migraine for at least 12 months meeting ICHD-3 criteria or clinically diagnosed migraine
  • Episodic migraine during 28-day screening with 6 to 14 headache days, including at least 4 migraine days
  • Not receiving preventive migraine medication for at least 5 half-lives before enrollment, or stable on no more than one preventive medication for at least 2 months
  • Body mass index between 17.5 and 37.5 kg/m2 and weight between 35 and 120 kg
  • Completed at least 85% of headache diary entries during screening
  • Able to comply with study procedures and restrictions
  • Able to understand and sign informed consent
  • No major cardiovascular, liver, or kidney disease
Not Eligible

You will not qualify if you...

  • Allergy or hypersensitivity to Gou-Teng-San or its ingredients
  • Botulinum toxin type A injections in head, face, or neck within 4 months
  • Use of opioid- or barbiturate-containing medications more than 4 days per month
  • Lack of efficacy after 3 months of treatment in 2 or more preventive medication classes
  • Use of migraine treatments like nerve block or transcranial magnetic stimulation within 2 months
  • Significant medical conditions that interfere with study participation
  • Participation in another drug or device clinical trial within 2 months or within 5 half-lives of investigational product
  • Use of other Chinese herbal medicines within 4 weeks
  • Previous exposure to monoclonal antibodies targeting CGRP pathway or receptor antagonists
  • History of alcohol or drug abuse in past 2 years
  • Breastfeeding, positive pregnancy test, or unwillingness to use contraception if of childbearing potential
  • Any condition deemed unsuitable by investigator for study participation or completion

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 4 weeks

Participants receive Gou-Teng-San or placebo orally twice daily for 4 consecutive weeks.

Weekly visits for 4 weeks

Trial Site Locations

Total: 1 location

1

Chung Shan Medical University Hospital

Taichung, South, Taiwan, 402306

Actively Recruiting

Loading map...

Research Team

C

Chueh-Yi Tsai, MD, MS

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Clin...

Episodic Migraine

Actively Recruiting

108 locations

Study to Evaluate the Efficacy and Safety of Intravenous Ept...

Episodic Migraine

Actively Recruiting

65 locations

A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Contr...

Episodic Migraine

Actively Recruiting

98 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here